Od-029931 Genotype-Guided Selection of Antidepressants: Is the Evidence Ready? Course
Type
Credit
Description
This course offers Continuing Professional Education credits. To claim the credits, the course must be completed prior to 1/31/2024. Once your evaluation is complete, log on to https://medstar.cloud-cme.com and toggle to your Transcript to find the credits the next business day.
Max Smith, PharmD, BCPS
Dr. D. Max Smith, PharmD, BCPS is a Clinical Pharmacogenomics Specialist at MedStar Health and Assistant Professor at Georgetown University Medical Center. Dr. Smith earned a PharmD at the University of Toledo and is a board-certified pharmacotherapy specialist. At the University of Florida, he completed a PGY-1 hospital residency and completed a PGY-2 residency and fellowship specializing in pharmacogenetics. His overarching research interest is studying implementation and clinical outcomes from the application of pharmacogenetic information in prescribing decisions. In his current role, he facilitates implementation and oversight of clinical pharmacogenetic testing throughout MedStar Health.
Objectives
- Explain foundational pharmacogenetic concepts.
- Discuss Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines for antidepressants.
- Compare combinatorial pharmacogenetics from open source pharmacogenetic tests for antidepressants.
Tags
Depression Antidepressants Pharmacogenetics Genotype SSRI SSNI Pharmacogenomics Metabolism Pharmacokinetics pharmacodynamics Black box Clinical outcomes Target dose PGx Initiatives psychiatry anxiety guidelines CPIC CE-Physician CE-RN CE-Pharmacy CE-Social Work CE-Dietician CE-PT CE-OT CE-ANY CE-PHYS CE-NURSE CE-PHARM CE-PHYS-ASSIST CE-SOCIAL-WORK